title: Immunohistochemical expression of promyelocytic leukemia body in soft tissue sarcomas.
abstract: BACKGROUND
  The function of promyelocytic leukemia (PML) bodies is not well known but plays an important role in controlling cell proliferation, apoptosis and senescence. This study was undertaken to analyze the clinical significance of PML body expression in primary tumor samples from malignant fibrous histiocytoma (MFH) and liposarcoma patients.
  
  
  METHODS
  We studied MFH and liposarcoma samples from 55 patients for PML bodies. Fluorescent immunostaining of PML bodies was performed in the paraffin-embedded tumor sections.
  
  
  RESULTS
  PML body immunostaining was identified in 63.9% of MFH and 63.2% of liposarcoma samples. PML body expression rates of all sarcoma cells were 1.5 +/- 1.8% (range: 0-7.0) in MFH and 1.3 +/- 1.4% (0-5.2) in liposarcoma samples. PML body expression (p = 0.0053) and a high rate of PML body expression (p = 0.0012) were significantly greater prognostic risk factors for death than the other clinical factors in MFH patients. All liposarcoma patients without expression of PML were disease free at the end of the study.
  
  
  CONCLUSIONS
  Our study suggests that the presence of PML bodies may indicate a poor prognosis for MFH and liposarcoma patients.
authors.affiliation: Department of Artificial Joints and Biomaterials, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan. tomatsuo@hiroshima-u.ac.jp
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Matsuo
authors.forename: Takashi
authors.initials: T
authors.lastname: Sugita
authors.forename: Shoji
authors.initials: S
authors.lastname: Shimose
authors.forename: Tadahiko
authors.initials: T
authors.lastname: Kubo
authors.forename: Masataka
authors.initials: M
authors.lastname: Ishikawa
authors.forename: Yuji
authors.initials: Y
authors.lastname: Yasunaga
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Ochi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D022003:Cell Nucleus Structures / Q000378:metabolism*; D005260:Female; D051677:Histiocytoma, Malignant Fibrous / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D008080:Liposarcoma / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000378:metabolism*; D000071156:Promyelocytic Leukemia Protein; D014157:Transcription Factors / Q000378:metabolism*; D025521:Tumor Suppressor Proteins / Q000378:metabolism*
chemical_list: D009687:Nuclear Proteins; D000071156:Promyelocytic Leukemia Protein; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; C070576:PML protein, human